Sixty-three patients, a median age of 65, and lymphoma that had come back or never responded. That was the group in a phase 1/2 trial of CTX110, an experimental CAR-T product made not from the patient’s own cells but from a healthy donor’s. The results, published online in Blood Advances, offer an early look at where “off-the-shelf” cell therapy stands.
The encouraging part first. Of 57 patients whose first infusion came at dose level 3 or above, 65% responded (37 of 57), and 39% had a complete response (22 of 57). Responses grew with the dose. Five of the 22 complete responders were still in complete response at a median follow-up of 34 months.
Why donor cells matter
Standard CAR-T works well in lymphoma, but each dose is custom-built. That brings manufacturing delays, cost and uneven product quality. A donor-derived product could sit ready in advance. As one industry commentary on the field put it, such a therapy might be held in inventory “the same way as a bottle of ibuprofen.” Patients with fast-moving disease cannot always wait weeks for their own cells to be processed, and some, after heavy chemotherapy, lack enough healthy T-cells to start with.
In plain terms, one donor collection could supply batches for dozens of patients, so a manufacturing slot would no longer decide who is treated and when.
The hard parts
Donor cells are foreign to the recipient. The body may reject them before they multiply, so doctors raise the dose of lymphodepleting chemotherapy ahead of the infusion. That does not solve graft-versus-host disease, in which the donor cells attack the patient’s tissue. Higher chemotherapy doses carry their own cost.
The trial reflects that cost. Cytokine release syndrome occurred in 54% of patients, mostly mild, and immune neurotoxicity in 13%. Neutropenia was the most common serious lab finding at 59%, followed by anemia and thrombocytopenia at 35% each. Serious adverse events hit 32% of patients.
Repeat dosing and what comes next
Two infusions at the top dose, given on days 1 and 35, seemed to hold responses longer than a single infusion: a median of 4.2 months against 1.7. Among nine patients retreated after their disease progressed, six responded again.
The authors say CTX110 gives a base for a next version, zugocabtagene geleucel, formerly CTX112, which carries extra edits to boost the cells’ growth and potency. They also flag limits. The study was small, single-arm and heavily pretreated, with no randomized comparison, and the response rates at higher doses only resembled those of approved CD19 CAR-T products.
Early findings suggest the approach is promising, not proven. Anyone weighing CAR-T options should talk to their doctor about which treatments they qualify for and which trials are open.
Sources
- ‘Off-the-Shelf’ CAR T Therapy Shows Early Activity in NHL
- Unlocking the scalability of allogeneic CAR-T | pharmaphorum
